Published in Cancer Weekly, December 6th, 2005
Presenting to peers at the U.K.'s annual review of Acute Myeloid Leukemia in Birmingham, U.K., Professor Alan K. Burnett, chairman of the U.K. National Cancer Research Institute Hematological Oncology Study Group, announced the median duration of response for clofarabine in these patients is currently 440 days.
This is an improvement on data, which were first presented to the American Society of Hematology in December 2004, which highlighted clofarabine's...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.